These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1871802)

  • 21. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys.
    Hausen B; Klupp J; Christians U; Higgins JP; Baumgartner RE; Hook LE; Friedrich S; Celnicker A; Morris RE
    Transplantation; 2001 Sep; 72(6):1128-37. PubMed ID: 11579312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation.
    van Gelder T; Zietse R; Mulder AH; Yzermans JN; Hesse CJ; Vaessen LM; Weimar W
    Transplantation; 1995 Aug; 60(3):248-52. PubMed ID: 7645037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies.
    Kootstra CJ; Van Der Giezen DM; Van Krieken JH; De Heer E; Bruijn JA
    Clin Exp Immunol; 1997 May; 108(2):324-32. PubMed ID: 9158106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study.
    Transplantation; 1997 Apr; 63(8):1087-95. PubMed ID: 9133469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection.
    Georgitis JW; Browning MC; Steiner D; Lorentz WB
    Ann Allergy; 1991 Apr; 66(4):343-7. PubMed ID: 1901692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and late humoral rejection: a clinicopathologic entity in two times.
    Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
    Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of anti-ICAM-1 and anti-LFA-1 monoclonal antibody therapy prolongs allograft survival in rat hind-limb transplants.
    Ozer K; Siemionow M
    J Reconstr Microsurg; 2001 Oct; 17(7):511-7; discussion 518. PubMed ID: 11598825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of an anti-LFA-1 antibody in renal allograft rejection in sheep.
    Grooby WL; Carter JK; Rao MM; Dewan P; Seymour AE; Brandon M; Russ GR
    Transplant Proc; 1992 Oct; 24(5):2304. PubMed ID: 1413070
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates.
    Berlin PJ; Bacher JD; Sharrow SO; Gonzalez C; Gress RE
    Transplantation; 1992 Apr; 53(4):840-9. PubMed ID: 1348883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of rejection in renal allograft biopsies using the presence of activated and proliferating cells.
    Serón D; Alexopoulos E; Raftery MJ; Hartley RB; Cameron JS
    Transplantation; 1989 May; 47(5):811-6. PubMed ID: 2655219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD; Rajagopalan PR; Hall M
    Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
    Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical role of OKT3.
    Norman DJ
    Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.